Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification

AIDS

Volumn 16, Issue 15, 2002, Pages 2035-2041

  Sklar, Peter A ^a   Ward, Douglas J ^a   Baker, Rose K ^a   Wood, Kathleen C ^a   Gafoor, Zarina ^a   Alzola, Carlos F ^a   Moorman, Anne C ^a   Holmberg, Scott D ^a   Tong, Tony ^a   Palella, Frank J ^a   Chmiel, Joan S ^a   Kalnins, Aleks ^a   Lichtenstein, Kenneth A ^a   Greenberg, Kenneth S ^a   Young, Benjamin ^a   Widick, Barbara ^a   Stewart, Cheryl ^a   Zellner, Peggy ^a   Yangco, Bienvenido G ^a   Halkias, Kalliope ^a   Lapierre, Cheryl ^a   Owen, Charles A ^a   Fuhrer, Jack ^a   Ording Bauer, Linda ^a   Kelly, Rita ^a   Esteves, Jane ^a   Tedaldi, Ellen M ^a   Walker Kornegay, Linda ^a   Marzouk, Joseph B ^a   Phelps, Roger T ^a   Rachel, Mark ^a   McCabe, Robert E ^a   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD4; Cohort study; Highly active antiretroviral therapy; HIV infections; Prevalence; Transient viremia; Viral load

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0037131203     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00008     Document Type: Article

References (11)

1. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 12:1619-1624.
2. Raboud JM, Rae S, Hogg RS, et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis 1999, 180:1347-1350.
3. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85.
4. Moorman A, Holmberg S, Marlowe S, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: The HIV Outpatient Study (HOPS). Ann Epidemiol 1999, 9:349-357.
5. Ward D, Sklar P. The significance of low-level viremia in patients with previously 'undetectable' HIV-1 RNA levels. XIII International Conference on AIDS. Durban, July, 2000 [abstract MoPpB1019].
6. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286:171-179.
7. Easterbrook P, Ives N, Peters B, et al. The natural history and clinical significance of intermittent virological 'blips' in patients who attain an initially undetectable viral load (VL) on HAART.. XIII International Conference on AIDS. Durban, July, 2000 [abstract WeOrB610].
8. Greub G, Cozzi Lepri A, Ledergerber B, et al. Low-level HIV viral rebound and blips in patients receiving potent antiretroviral therapy. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 522].
9. Chaisson RE, Keruly J, Moore RD. Immunologic response to HAART by duration of viral suppression and continuity of antiretroviral therapy. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 429].
10. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2001.
11. Havlir DV, Little S, Hwang J, et al. HIV specific immune responses in subjects with high-level viral suppression with or without intermittent viremia treated for 3-5 years with HAART. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 521].